Manuel Scorrano, Elena Montagni, Abenezer Tarekegne Legesse, Ludovica Iovino, Chiara De Cesari, Ilaria Tonazzini, Anna Letizia Allegra Mascaro, Laura Baroncelli
{"title":"Cortical dynamics in Angelman syndrome: novel insights from a preclinical mouse model.","authors":"Manuel Scorrano, Elena Montagni, Abenezer Tarekegne Legesse, Ludovica Iovino, Chiara De Cesari, Ilaria Tonazzini, Anna Letizia Allegra Mascaro, Laura Baroncelli","doi":"10.1038/s41398-026-04254-5","DOIUrl":null,"url":null,"abstract":"<p><p>Angelman syndrome (AS) is a neurogenetic disorder caused by the loss of function in the maternally inherited UBE3A gene, leading to a spectrum of symptoms that include developmental delays, intellectual disability, and motor impairments. While genetic and molecular mechanisms of AS are increasingly well characterized, a critical gap remains in understanding how disruptions in neuronal connectivity at the circuit level contribute to its pathophysiology. Here, we aimed to address this gap by investigating cortical connectivity alterations in a mouse model of AS. Using wide-field calcium imaging, we monitored real-time neuronal activity across the entire dorsal cortex in awake animals. Our results revealed widespread cortical hyperconnectivity in AS mice compared to wild-type controls, particularly in regions involved in motor and sensory processing. Notably, this pattern of aberrant connectivity persisted across two distinct time points in adulthood, suggesting a stable and enduring network dysfunction. These findings indicate that the absence of UBE3A function drives persistent disruptions of functional connectivity, which may underlie key clinical manifestations of AS.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710969/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-026-04254-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Angelman syndrome (AS) is a neurogenetic disorder caused by the loss of function in the maternally inherited UBE3A gene, leading to a spectrum of symptoms that include developmental delays, intellectual disability, and motor impairments. While genetic and molecular mechanisms of AS are increasingly well characterized, a critical gap remains in understanding how disruptions in neuronal connectivity at the circuit level contribute to its pathophysiology. Here, we aimed to address this gap by investigating cortical connectivity alterations in a mouse model of AS. Using wide-field calcium imaging, we monitored real-time neuronal activity across the entire dorsal cortex in awake animals. Our results revealed widespread cortical hyperconnectivity in AS mice compared to wild-type controls, particularly in regions involved in motor and sensory processing. Notably, this pattern of aberrant connectivity persisted across two distinct time points in adulthood, suggesting a stable and enduring network dysfunction. These findings indicate that the absence of UBE3A function drives persistent disruptions of functional connectivity, which may underlie key clinical manifestations of AS.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.